Over the past decades, human papillomavirus (HPV) vaccines have been approved in numerous countries, producing two very positive trends.
According to Merck's financial results for 2024, its market-leading HPV vaccines, GARDASIL and GARDASIL 9, produced $8.6 billion in sales, with higher demand in most international regions, particularly Japan.
Read More
